Picture of Crescita Therapeutics logo

CTX Crescita Therapeutics Income Statement

0.000.00%
ca flag iconLast trade - 00:00
HealthcareAdventurousMicro CapContrarian

Annual income statement for Crescita Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue22.315.616.823.517.5
Cost of Revenue
Gross Profit16.5119.6913.210.4
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses1915.317.522.919.1
Operating Profit3.290.344-0.7730.631-1.53
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes3.180.52-1.010.404-1.53
Provision for Income Taxes
Net Income After Taxes1.850.037-1.10.862-1.99
Net Income Before Extraordinary Items
Extraordinary Items
Net Income1.850.037-1.10.862-1.99
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income1.850.037-1.10.862-1.99
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS0.1150.009-0.0880.041-0.098